ANNUAL
MEETING 2016
September 19 & 20
THE WESTIN KIERLAND
SCOTTSDALE, AZ
PCMA Members
The Pharmaceutical Care Management Association is the national association
representing America’s pharmacy benefit managers. PBMs administer prescription
drug plans for more than 266 million Americans with health coverage provided through
Fortune 500 employers, health insurance plans, labor unions, and Medicare Part D.
Welcome to the PCMA Annual Meeting 2016
The PCMA Annual Meeting is the industry’s premier executive conference. The event is tailored specifically for
senior executives from PBMs and their affiliated business partners — most notably drug manufacturers. We’ve
designed the Annual Meeting to be an important part of your business strategy and are proud of the unique value
that the conference offers to PBM, specialty pharmacy and pharma industry executives.
The decision makers in attendance, educational insights, and business opportunities are ultimately what make the
Annual Meeting so valuable. There are many pressing issues impacting the health care industry today, key among
them are innovation and affordability, access and value. These and many other issues will be addressed both on and
off the stage during the next two days. The interaction and dialogue that takes place at this event serves to promote
continued industry collaboration addressing the many challenges we face.
We thank you for coming to this year’s Annual Meeting. We hope that you find your time spent to be enlightening
and beneficial to your business. Enjoy your time in Scottsdale.
Contents
2Schedule-at-a-Glance
29
PCMA Board of Directors
5Maps
30
PCMA Staff
8
General Information
31
PCMA Members
9
Session Details
32
2016 PCMA Affiliates
33
Conference Sponsors
19Speakers
 1
Schedule-at-a-Glance
MONDAY, SEPTEMBER 19
7:00 am – 7:00 pm
Registration Open
Culturekeepers Hall West
7:00 am – 6:30 pm
Private Meeting Rooms Open
7:30 am – 9:00 am
Networking Breakfast
Trailblazer C
9:00 am – 12:00 pm
GENERAL SESSIONS
Kierland Grand 2/3
9:00 am – 9:15 am
Welcome
Conference Moderator: Betty Nguyen, Anchor and Journalist, NBC News & MSNBC
9:15 am – 9:45 am
How PBMs Deliver Clinical Value Through Specialty Pharmacy
Alan Lotvin, Executive Vice President, CVS/specialty, CVS Health
9:45 am – 10:15 am
The World of Pharmacy and Pharmaceuticals in 2030
Bill Roth, Founding Partner, Blue Fin Group
10:15 am – 11:00 am
Value-based Contracting: U.S. Landscape Realities
Jim Clement, Executive Director, Cost of Care and Supply Chain Strategy, Aetna
Pharmacy Management, Aetna
Mike Ryan, Senior Vice President, U.S. Value, Access and Policy, Bristol-Myers Squibb
Moderator: Tom Knox, President, Fathom Healthcare Solutions
11:00 am – 11:30 am
Policy Trends to Watch in 2017
Larry Kocot, Principal and National Leader, Center for Healthcare Regulatory Insight,
KPMG
11:30 am – 12:00 pm
The Business of BioPharma: Building a Healthy Future for Patients, Payers and Society
George Scangos, Chief Executive Officer, Biogen
Moderator: Jerry Miller, President, J. Miller Consulting
12:15 pm – 1:45 pm
Member Company Lunch Receptions
Aetna: Kierland Grand 1B
Humana Pharmacy Solutions: Trailblazer DE
MedImpact: Kierland Grand 1C
OptumRx: Trailblazer C
Networking Lunch: Kierland Grand 1A and Culturekeepers Hall West
2 Schedule-at-a-Glance
1:45 pm – 6:30 pm
Afternoon is open for private meetings and networking
6:30 pm – 9:00 pm
Cocktail and Dinner Reception with Live Music
Northern Sky Terrace
TUESDAY, SEPTEMBER 20, 2016
7:00 am – 4:00 pm
Registration Open
Culturekeepers Hall West
7:00 am – 8:00 pm
Private Meeting Rooms Open
7:00 am – 8:45 am
Networking Breakfast
Trailblazer C
8:45 am – 11:45 am
GENERAL SESSIONS
Kierland Grand 2/3
8:45 am – 9:45 am
PCMA Leadership Session
The Political and Policy Environment
Mark Merritt, President & Chief Executive Officer, PCMA
The PBM/Pharma Relationship in the Era of High Price Drugs
William Fleming, Segment Vice President, Humana Inc. & President, Humana Pharmacy
Solutions
Tim Wentworth, President & Chief Executive Officer, Express Scripts
Moderator: Kent Rogers, Senior Vice President, Industry Relations, OptumRx
9:45 am – 10:30 am
Challenges Related to Outcomes Contracting in the U.S. and Solutions for Addressing
Them
Chris Bradbury, Leader, Integrated Clinical Solutions and Specialty Pharmacy, Cigna
Pharmacy Management, Cigna
Claudio Faria, Senior Director, U.S. Health Economics Outcomes Research, Celgene
Pierre Leurent, Chief Executive Officer, President of the Management Board & Founder,
Voluntis
Moderator: Eric Elliott, Chief Executive Officer, LMK Advisory & Chairman, Voluntis
10:30 am – 11:00 am
ACOs and IDNs: Understanding Payer Moves Toward Value-based and Outcomes
Contracting
Charles Kennedy, Vice President & Chief Medical Officer for Clinical Integration, Aetna
11:00 am – 11:45 pm
Perspectives from Wall Street
George Hill, Director, Deutsche Bank
Bob Jones, Vice President, Goldman Sachs & Co.
Schedule-at-a-Glance 3
12:00 pm – 1:30 pm
Member Company Lunch Receptions
CVS Health: Trailblazer DE
Express Scripts: Trailblazer C
MagellanRx Management: Kierland Grand 1B
Prime Therapeutics: Kierland Grand 1C
Networking Lunch: Kierland Grand 1A and Culturekeepers Hall West
1:30 pm – 8:00 pm
Afternoon is open for private meetings and networking
8:00 pm – 10:00 pm
Cocktail and Dessert Reception
Lobby Lounge & Terrace
Don’t miss these important networking events!
Monday
12:15 pm – 1:45 pm
Tuesday
12:00 pm – 1:30 pm
Monday evening
6:30 pm – 9:00 pm
Northern Sky Terrace
Cocktail and
Dinner Reception
Live music, food stations,
and views of the lake and golf
course provide a relaxed and
fun atmosphere, perfect for
business networking, during this
special reception and dinner.
4 Schedule-at-a-Glance
Member Company
Lunch Receptions
These receptions offer excellent
opportunities for interactions
between PBM member and drug
manufacturers. Manufacturer
attendees will flow in and out
of the concurrent receptions
whereas members are asked to
post in their designated room
during the reception time.
Tuesday evening
8:00 pm – 10:00 pm
Lobby Lounge & Terrace
Cocktail and
Dessert Reception
Join your peers for dessert,
cocktails, and conversation
at an after-dinner reception.
Maps
LOBBY LEVEL
Explorers Terrace
B
Tribal
A
B
Mapmakers
Expedition Hall
Pathfinders
A
Merriam
A
B
Whipple
A
B
The
Rim
Bar
Scotch
Library
Lobby Lounge
A
A
A
Trailblazers Terrace
Lowell
B
Powell
Cushing
A
Trailblazers West
Sitgreaves
Discovery Hall
Parke
Stargazers Terrace
B
B
E
B
Trailblazers South
Hall Of State
Concierge
Coffee
Flats &
Snowbowls
Entry
Toonerville 66
Trading Post
Front Desk
1A
1B
1C
2
Vista Morada Patio
Activities listed in the schedule-at-a-glance
Culturekeepers Hall West
Kierland Grand Ballroom
Private meetings rooms
Shared meeting rooms
3
4A
4B
4C
2087 DD
2085 DD
2083 DD
2081 TK
2086 TD
2084 TK
2082 TK
CL
2088 TKA
CL
2089 DD
2120 TD
2090 TK
2118 TK
2119 TD
2091 DD
2117 TK
2092 TDA
2116 TD
2093 DD
2114 TK
2115 TD
2094 TK
2112 TD
2113 TK
2095 DD
2110 TK
2111 TD
2096 TD
2108 TD
2109 DK
2097 DK
2106 TD
2107 TD
2098 TK
2105 TD
2099 DK
2100 DK
2101 DD
2102 DD
2103 DK
2104 DK
Culturekeepers Hall South
2121 TK
2122 TK
2123 TD
2124 TK
2125 TD
COURTYARD
EXIT
Tangent
FedEx
Business
Center
D
C
To additional meeting rooms
Kierland
Mining Co.
Trailblazers Ballroom
To Lobby
Maps 5
LOWER LEVEL
Northern Sky Terrace
Terrace
Terrace
Terrace
Billiards
Waltz & Weiser
Cantina
Activities listed in the schedule-at-a-glance
Private meetings rooms
6 Maps
B
C
Greenway
A
2
Herberger
Ballroom
A
4
1
3
B
5
West Foyer
A
B
Kirkland
Noble
Terrace
Dreamweavers Canyon
Private
Dining
Muddle
Bar
Private
Dining
Shared meeting rooms
Rainmakers
Ballroom
Visionaries Hall
Terrace
Nellie
Cashman’s
Monday
Club Cafe
East Foyer
North Foyer
Deseo
Enhance Your Conference Experience
View the list of
who’s attending
Message with other attendees
Review the agenda and create
a personalized schedule
Access hotel maps and
meeting room locations
Stay informed of any lastminute schedule changes
Check out the sponsors
Download our NEW app for access on the go!
Stop by the reg desk if you need help downloading the app.
General Information
Registration Desk Hours
Presentations
The PCMA registration desk will be open in
Culturekeepers Hall West each day of the conference
during the hours listed below. Should you have any
questions, please stop by the registration desk and staff
will be able to assist you.
Presentations authorized for distribution will be posted
online and in the conference app after the conference.
Attendees will be notified by email once presentations
are available.
Sunday, September 18
4:00 pm – 7:00 pm
Monday, September 19 7:00 am – 7:00 pm
Tuesday, September 20
7:00 am – 4:00 pm
Photography
Professional photographs taken during the conference
may be posted online and/or printed in future materials.
Disclaimer
If you require a copy of your registration confirmation,
receipt of payment, or invoice, please email Diane
Fulton, [email protected].
The opinions expressed by program participants
are those of the individual presenters. They do not
necessarily reflect the views of PCMA or its members.
Security
Attendance at a Pharmaceutical Care Management
Association (PCMA) meeting or event includes the
limited, non-exclusive, revocable, and nontransferable
right and license to use any PCMA materials, whether
written, oral or electronic, made available by PCMA
to the attendees for informational or personal use
purposes only. PCMA reserves all other rights.
PCMA or its licensors own all rights in and to all of
its presentations, content, designs, methodologies,
processes, programs, products, information,
and documentation. PHARMACEUTICAL CARE
MANAGEMENT ASSOCIATION, PCMA and all other
names, logos, and icons identifying PCMA and its
products and services are proprietary trademarks of
PCMA, and any use of such marks without the express
written permission of PCMA is strictly prohibited.
In order to provide a secure environment, conference
participants MUST wear name badges when attending
any conference function, including sessions, meals,
evening receptions, and private meetings in member
and sponsor meeting room facilities. Security will
monitor entrances to all conference activities. Please do
not misplace or forget badges, as duplicates will not be
provided.
Neon orange badges indicate drug manufacturers. Beige
badges indicate PBM, payer, specialty pharmacy, and
other industries.
Shuttle Transportation
Shuttle service is provided to and from Marriott
McDowell Mountain on Monday and Tuesday every 15
minutes beginning on the hour at 6:00 am and ending
at 10:00 pm from the following locations:
»» The Westin Kierland: South Terrace, just outside the
Kierland Grand Ballroom
»» Marriott McDowell Mountain: Main Entrance
Internet
Complimentary Wi-Fi is available throughout the Westin
Kierland and in the guestrooms. In the conference
center and meeting rooms, please use the password
pcmaAM2016 to access the Wi-Fi. It can be accessed
without a password while in the lobby and other public
spaces.
8 General Information
SESSION DETAILS
Session Details
Session Details
Monday, September 19
9:15 am – 9:45 am
Kierland Grand 2/3
How PBMs Deliver Clinical Value Through Specialty Pharmacy
Alan Lotvin, Executive Vice President, CVS/specialty, CVS Health
Pharmacy benefits are, first and foremost, about helping patients manage their conditions. Specialty pharmacies
and PBMs are applying their expertise and assets toward progressive solutions to help their clients support the
clinical needs of patients while managing costs. All major specialty pharmacies offer many valuable solutions in
regards to managing REMS, patient adherence, and drug delivery. However, patients and payers realize the most
savings and clinical value when specialty pharmacies and PBMs combine.
This session will highlight the value payers and patients receive, such as indication-based solutions, managing
utilization across benefits, and a robust approach to supporting patients beyond adherence, with a specialty
pharmacy/PBM relationship. Combined, all of these approaches help support patient care and control overall
specialty costs rather than a singular focus on drug costs or costs associated with specialty drug non-adherence.
Session Details 9
Monday, September 19
9:45 am – 10:15 am
Kierland Grand 2/3
The World of Pharmacy and Pharmaceuticals in 2030
Bill Roth, Founding Partner, Blue Fin Group
This session will explore a broad view of where our industries are headed in regard to innovation, the business
models we’ll need to support it, and the importance of our alignment in order to balance society’s priorities.
Combining the view of the cost of health care spiraling to $4.4 trillion by the end of the decade, with continued
innovation on the way in the areas of proteonomics, genomics and precision medicine, biosynthetics, AI, and
more, Bill will explore likely scenarios for how they could impact our own strategies as manufacturers, payers
and consumers.
10 Session Details
Monday, September 19
10:15 am – 11:00 am
Kierland Grand 2/3
Value-based Contracting: U.S. Landscape Realities
Jim Clement, Executive Director, Cost of Care and Supply Chain Strategy, Aetna Pharmacy Management, Aetna
Mike Ryan, Senior Vice President, U.S. Value, Access and Policy, Bristol-Myers Squibb
Moderator: Tom Knox, President, Fathom Healthcare Solutions
Though still in their infancy in the U.S. health care system, value-based risk sharing agreements are growing in
popularity. Market forces have been driving stakeholders to explore new types of financing and access, shifting risk
towards value, indications, and/or outcomes-based arrangements. These varying types of value-based arrangements
have different goals and metrics for success. Some might allow a payer to minimize risk or manage risk differently;
others allow manufactures to create product differentiation and to potentially obtain the full value of the product;
while others still might allow for population versus patient management and improved data repositories and
informatics systems. Success depends on good contract design, availability of data, and administration.
During this session the panel will discuss the pros and cons of value-based contracts from their varying
perspectives. Some of the questions they will address include what’s driving the demand for these types
of contracts, how are players looking at specialty versus non-specialty therapies as candidates for these
arrangements, what are some of the barriers to doing value-based contracts in the current U.S. landscape,
what are the manufacturer versus payer expectations of one another in engaging in these agreements, and
finally, how do they see these arrangements evolving over time and with greater adoption.
Session Details 11
Monday, September 19
11:00 am – 11:30 am
Kierland Grand 2/3
Policy Trends to Watch in 2017
Larry Kocot, Principal and National Leader, Center for Healthcare Regulatory Insight, KPMG
Driven by the high cost of drugs, the prescription drug industry, including PBMs, is being discussed in Washington
DC and State capitols at a level not seen in recent years. New proposals for legislative and regulatory reform seem
to come each day. In this environment it can be difficult to decipher what legislative and regulatory policy actions
are happening now and in the near future that will directly impact our business.
During this session Larry will discuss a number of policy trends that will impact healthcare markets in the next year,
with specific implications for PBMs and pharmaceutical manufacturers.
12 Session Details
Monday, September 19
11:30 am – 12:00 pm
Kierland Grand 2/3
The Business of BioPharma: Building a Healthy Future for Patients, Payers and Society
George Scangos, Chief Executive Officer, Biogen
Moderator: Jerry Miller, President, J. Miller Consulting
The biopharma industry is currently in an historic period of innovation, with deep pipelines across many difficult-totreat disease areas. However, there are numerous challenges that may impact whether promising drug candidates
ever get to the patients who need them. As the CEO of Biogen and the current Chairman of PhRMA, Dr. Scangos
has a unique view into the challenges of drug development, the current policy environment and the appropriate
balance between innovation, access, and cost.
Session Details 13
Tuesday, September 20
8:45 am – 9:45 am
Kierland Grand 2/3
PCMA Leadership Session
The Political and Policy Environment
Mark Merritt, President & Chief Executive Officer, PCMA
The PBM/Pharma Relationship in the Era of High Price Drugs
William Fleming, Segment Vice President, Humana Inc. & President, Humana Pharmacy Solutions
Tim Wentworth, President & Chief Executive Officer, Express Scripts
Moderator: Kent Rogers, Senior Vice President, Industry Relations, OptumRx
The high cost of drugs is an unavoidable subject for the PBM/payer and pharma industries today. The drug pipeline
of recent years has brought us breakthrough therapies that are delivering tremendous value to our health care
system, albeit at high prices. At the same time, we’re experiencing high costs associated with drugs offering little
incremental value, and irresponsible pricing practices from bad actors in the industry. These and many other factors
are contributing to a business and political environment that threatens the ability to reward innovation in the
pharma industry, and continue the use of free market solutions that our system has benefited from for so long.
Our industries share a common goal, the sustainability of the free market health care system that rewards
innovation and improved outcomes and the lives of patients.
During this session, the outgoing and incoming PCMA Board Chairmen will share their views on industry trends,
the PBM value proposition, and the evolving relationship between manufacturers and PBMs.
14 Session Details
Tuesday, September 20
9:45 am – 10:30 am
Kierland Grand 2/3
Challenges Related to Outcomes Contracting in the U.S. and Solutions for Addressing Them
Chris Bradbury, Leader, Integrated Clinical Solutions and Specialty Pharmacy, Cigna Pharmacy Management, Cigna
Claudio Faria, Senior Director, U.S. Health Economics Outcomes Research, Celgene
Pierre Leurent, Chief Executive Officer, President of the Management Board & Founder, Voluntis
Moderator: Eric Elliott, Chief Executive Officer, LMK Advisory & Chairman, Voluntis
During yesterday’s session we heard about the realities of the landscape for value-based contracts. While these
types of contracts offer many opportunities, there are also significant difficulties in getting these contracts to
the desired design and final stage. This panel will explore some of the biggest challenges and solutions for these
contracting approaches — including the varying payer needs for an individual product, the high level of specificity
needed, and data collection.
Helping to frame this conversation are three individuals, two from well-known companies with a clear view for how
they could work and one from a company with capabilities and a business model to help solve one (hopefully last)
hurdle on our way to extensive penetration of outcomes based contracts.
Session Details 15
Tuesday, September 20
10:30 am – 11:00 am
Kierland Grand 2/3
ACOs and IDNs: Understanding Payer Moves Toward Value-based and Outcomes Contracting
Charles Kennedy, Vice President & Chief Medical Officer for Clinical Integration, Aetna
Hospitals, physician practices, and long term care facilities are continuing to consolidate under Integrated Delivery
Networks (IDNs). Like the rest of the industry, health system reimbursement practices are moving towards outcomes
and value-based care. There are currently two major themes in the evolution of health care payment methodologies:
increasing accountability for both quality and total cost of care, and a greater focus on population health
management as opposed to payment for specific services. Moreover, CMS’s strategy — to increasingly link physician
financial reward to the value of the services they provide in keeping individuals and populations healthy — opens
the door to structural re-alignment of health care delivery.
These advanced alternative payment models come with substantial risk elements. During this session, Dr. Kennedy
will talk in detail about the challenges in aligning individualized value-based decision making and population based
payment. He will share case studies demonstrating why individual, value-based analytics matter, and he will provide
examples of newly available electronic patient datasets combined with new analytic frameworks that can result in
successful health care knowledge bases that make the individual consumer centric experience a reality. Finally, he
will share his perspectives on the role of pharma in this evolving reimbursement landscape.
16 Session Details
Tuesday, September 20
11:00 am – 11:45 am
Kierland Grand 2/3
Perspectives from Wall Street
George Hill, Director, Deutsche Bank
Bob Jones, Vice President, Goldman Sachs & Co.
Due to their unique vantage point, Wall Street analysts offer a distinctive perspective of our industries. During this
session, George and Bob will share their thoughts on the most important trends impacting the intersection of PBMs
and manufacturers. Some of the ideas that will be addressed include:
»» Impact of managed care consolidation;
»» Thoughts on channel consolidation;
»» Thoughts on industry pricing structures and models;
»» The value proposition PBMs are making to their clients around clinical management and specialty pharmacy —
outcomes and indication-based contracts;
»» Formulary consolidation;
»» ePA process and how PAs impact manufactures; and
»» Biosimilars.
Session Details 17
18 Session Details
SPEAKERS
Speakers
Speakers
Chris Bradbury
Leader, Integrated Clinical Solutions and Specialty Pharmacy, Cigna Pharmacy
Management
Cigna
Chris Bradbury is currently the Integrated Clinical Solutions and Specialty Pharmacy Leader
within Cigna Pharmacy Management. He serves as an Executive Committee member of Cigna
Pharmacy, one of the nation’s largest pharmacy benefit managers and specialty pharmacies.
Prior to joining Cigna in 2013, Bradbury spent fifteen years at Medco Health Solutions where
he led many of the PBM’s clinical and integrated data patient safety solutions as well as the population health,
chronic care management and care coordination solutions. In addition, he served as a management consultant
focused on business strategy, process reengineering, strategic sourcing, and benchmarking in the healthcare and
financial services industries.
Bradbury earned his Bachelor of Business Administration in Finance from Georgetown University and earned his
Master of Business Administration from MIT’s Sloan School of Management.
Jim Clement
Executive Director, Cost of Care and Supply Chain Strategy, Aetna Pharmacy
Management
Aetna
As Executive Director of Cost of Care and Supply Chain Strategy for Aetna Pharmacy
Management, Jim Clement is responsible for leading Aetna’s enterprise relationships with
pharmaceutical manufacturers and setting formulary management strategy. Clement is
responsible for all rebate and fee-for-service contracting and administration, specialty and
clinical program partnerships and coordination of business-to-business strategies, including international and
ACO strategies.
Prior to joining Aetna, Clement worked at Genentech in channel and distribution management focusing on the
PBM and specialty pharmacy segments and serving as an in-house consultant in forming payer contracting and
negotiating strategies. Prior to Genentech, he was the Director of Pharmaceutical Contracting at Express Scripts
where he was responsible for rebate contracting and manufacturer relations.
Clement is a graduate of the University of Missouri-Columbia and holds a Master of Health Administration from
Saint Louis University School of Public Health.
Speakers 19
Eric Elliott
Chief Executive Officer, LMK Advisory &
Chairman, Voluntis
Eric Elliott is currently the Chief Executive Officer of LMK Inc, and Chairman of Voluntis.
Separately, he is working independently with investors to evaluate potential assets for
ownership and leadership. Voluntis is a French-based medical device/software algorithum
driven tool that accelerates the effectiveness of medications. Initially targeted at diabetes and
oncology, it is being utilized extensively in the E.U. markets, and in some applications in the
U.S. It is under FDA review for extended U.S. market release in 2016.
Prior to his current roles, Elliott led three organizations operating in the pharmacy benefit management industry.
In his most recent role as Prime Therapeutics’ President and Chief Executive Officer (April 2010 - April 2015),
he was responsible for all operating and strategic aspects of the full service pharmacy benefit management (PBM)
company. With approximately $19 billion in annualized drug spend under management at the time of his departure,
Prime was the fourth largest pharmacy benefit manager in the United States. Prime was servicing 23 health plans,
other PBMs, and several large employer direct customers. Previously, Elliott held the role of president at Cigna
Pharmacy Management (2006-2010) and Aetna Pharmacy Management (2003-2006)
With experience running three integrated PBMs, he is skilled in leading and growing businesses, to include line
and segment expansions. His aggressive and innovative business leadership is focused on helping clients obtain the
maximum value from their pharmacy benefits and enabling individuals to get the critical medicine they need, while
creating a work environment that attracts and retains the very best.
Under Elliott’s leadership, Prime was recognized locally and nationally by prominent publications and organizations
for its employee engagement, healthy workplace, highest quality and care of service for members, and business
growth. During his tenure, Prime Therapeutics more than doubled in size and accelerated the value created by the
organization more than four fold.
Elliott received his bachelor’s degree in Management and Finance, and a Master of Business Administration from
Temple University in Philadelphia. He served for many years on the board of directors at Prime, PCMA, and the
Twin Cities American Heart Association. He continues to serve on the board of The Main Street America Group
and Voluntis.
Claudio Faria
Senior Director, U.S. Health Economics Outcomes Research
Celgene
Claudio Faria is the Senior Director, of U.S. Health Economics Outcomes Research for
Celgene. In this role he leads U.S. outcomes research and Market Access HEOR customer
initiatives.
Faria joined Celgene after many years as Director of Oncology at Eisai. He has extensive
experience in HEOR in the pharmaceutical industry both in the U.S. and internationally. He
also has expertise in the development of product value propositions and in successfully leading teams in delivering
value propositions to market access customers and key decision makers.
Prior to his experience at Eisai, Faria developed and was Associate Director of Clinical Research and Health
Outcomes at the University of Massachusetts Medical School. He was also a Medical Science Liaison at ScheringPlough Corporation and a Senior Research Pharmacist of Investigational Drug Service at Brigham & Women’s
Hospital and Dana-Farber Cancer Institute in Boston.
Faria has held faculty positions at the Massachusetts College of Pharmacy and Northeastern University. He is also
well published in medical literature.
20 Speakers
William Fleming
Segment Vice President, Humana Inc.
President, Humana Pharmacy Solutions
Dr. William K. Fleming, PharmD, is Segment Vice President for Humana Inc. and President,
Humana Pharmacy Solutions, where he is responsible for Humana’s pharmacy operations and
business strategy that services all Humana segments, including its non-Humana membership.
Fleming serves on Humana’s Management Team (Segment President).
A 22-year Humana rookie, Fleming has spent the majority of his pharmacy career pioneering
Humana’s pharmacy business. He has worked in partnership with Humana’s retail segment to deliver an industryleading Part D business. Prior to Humana, he had various opportunities in hospital pharmacy, retail pharmacy,
Medicaid pharmacy benefit management, and nuclear pharmacy.
Fleming received his BS Pharmacy from the University of Kentucky College of Pharmacy where he went on to
receive his Doctor of Pharmacy. He also holds a BA in General Studies from Transylvania University with an
emphasis in Biology and Economics. William currently serves on the Board of Directors of PCMA and PQA (the
Pharmacy Quality Alliance) and has held prior Board/Trustee appointments to various pharmacy and charity
organizations.
George Hill
Director
Deutsche Bank
George Hill has more than 15 years of Wall Street experience and more than 17 years of
health care industry experience. Hill joined Deutsche Bank in September 2013 as the senior
analyst covering health care technology and distribution.
Hill previously worked at Citi Research from November 2010 to July 2013 as a senior
analyst covering the health care technology and distribution sector. Prior to joining Citi, Hill
worked six years at Leerink Swann where he was the senior health care services analyst and also spent time as the
senior calling officer for Leerink’s health care services investment banking efforts. Prior to Leerink, Hill worked
on the health care services research team at Thomas Weisel Partners and worked as an analyst at Citigroup Asset
Management. Before working on Wall Street, Hill worked as a consultant and journalist in the pharmaceutical
services sector.
Hill received his BA from Rutgers University.
Bob Jones
Vice President
Goldman Sachs & Co.
Robert P. Jones joined Goldman Sachs & Co. in April 2008 and was promoted to Vice
President in January 2010. Prior to joining the firm, Jones worked at UBS Securities LLC as
an Associate Analyst in the generic pharma manufacturers, PBMs, distributors and labs group.
He also held previous roles within Johnson & Johnson Company, including Senior Analyst in
the strategic planning and business analytics group.
Jones graduated from Lehigh University with a Bachelor of Science in Finance in 1999.
Speakers 21
Charles Kennedy
Vice President & Chief Medical Officer for Clinical Integration
Aetna
Charles D. Kennedy, MD, is Vice President and Chief Medical Officer for Clinical Integration.
In this role, Kennedy is responsible for planning the integration of the Aetna and Humana
clinical businesses after the close of the proposed transaction. The primary goal of the Aetna
and Humana transaction is to offer consumers a broader choice of products, access to higher
quality and more affordable care, and a better overall experience in more geographic locations
across the country. Kennedy has a dual reporting relationship to Rick Jelinek, Executive Vice President, Humana
Integration, and to Dr. Hal Paz, Executive Vice President, Chief Medical Officer.
Previously, Kennedy was Chief Population Health Officer, Healthagen, responsible for leading population health and
care management strategies and working with health systems and provider organizations to design and implement
population health management programs
Kennedy is a recognized expert in health care and health information technology. He was a founding commissioner
of the Certification Commission for Health Information Technology (CCHIT), the first organization recognized by the
federal government to certify EMRs. He recently concluded a two term commitment as the health insurance industry
representative on the HIT Policy Committee, a Federal Advisory Committee that is guiding CMS policies to allocate
$40 billion in federal funding for HIT deployment. Kennedy serves on the AHIP Foundation Board of Directors and
on the advisory board for the Center for Healthcare Innovation, Healthcare and Life Science Innovation Lab.
Kennedy holds an MD in Internal Medicine from the University of California at Los Angeles, an MBA in Corporate
Strategy and Health Care Economics from Stanford University, and a bachelor’s degree in Genetics from the
University of California at Berkeley. He has been featured and quoted on the topics of health care technology and
operations in news publications and outlets that include ComputerWorld, Bloomberg, Associated Press, The Pink
Sheet, The Industry Standard, Modern Healthcare, HealthLeaders.
Tom Knox
President
Fathom Healthcare Solutions
As President at Fathom Healthcare Solutions Inc., Tom Knox is responsible for leading all
market access, reimbursement, and health policy aspects for pharmaceutical, biotech, and
medical device organizations. Knox’s long history of cross-functional leadership positions
allows him to guide clients in their effort of balancing the complex interplay of payers, health
care professionals, and patients. His in-depth knowledge of access and reimbursement will
help organizations strengthen the organizational leadership role of managed care functions beyond just being
“account” and “contracting” experts. Utilizing a cross-functional stakeholder orientation combined with his
experience implementing several integration processes enables Knox to provide companies the ability to quickly
re-gain maximum functionality.
Prior to starting Fathom Healthcare Solutions, Inc., Knox worked as Vice President, Managed Markets, Health Policy
and Government Affairs for Allergan, Inc. During his more than nine years at Allergan, Knox was responsible for
strategy and execution related to reimbursement and policy supporting business units in ophthalmology, neurology,
urology, medical dermatology, and medical aesthetics. Tom has experience in the development of strategy related to
all aspects of Medicare, Medicaid, commercial, specialty pharmacy, and health policy.
Prior to Allergan, Knox helped to establish two new businesses, HealthNexis a company founded by Cardinal
Health, McKesson and AmeriSourceBergen, and aaiPharma a specialty pharmaceutical company focused on pain
management. For 15 years Knox worked at Novartis Nutrition in multiple roles related to sales and marketing,
account management and business unit leadership.
Tom attended the University of Illinois-Chicago, Cardinal Stritch University and Executive Leadership courses at
Harvard University.
22 Speakers
Larry Kocot
Principal and National Leader, Center for Healthcare Regulatory Insight
KPMG
S. Lawrence Kocot is a Principal at KPMG, LLP and National Leader of KPMG’s Center for
Healthcare Regulatory Insight. The Center follows health care regulatory and policy trends
driving health care transformation and industry convergence and the broader implications
of operating in a more collaborative and integrated U.S. healthcare payment and delivery
environment.
Kocot provides strategic advice and counsel to companies on regulatory matters relating to public health care
programs, including Medicare and Medicaid. Kocot has served as counsel to a wide range of corporations and
associations on a variety of different matters, including investigations by the FTC, DOJ, SEC, and state attorneys
general, as well as on qui tam and other litigation. Additionally, Kocot has represented companies in audits and
other disputes with the federal government and counseled organizations on the development and formation of
accountable care organizations and other alternative payment arrangements.
Kocot is a former Senior Advisor to the Administrator of CMS at the U.S. Department of Health and Human
Services. In this capacity, he was involved in a wide range of health care policy issues and operations related to
Medicare and Medicaid. Notably, Kocot was a key member of the management and operations team responsible
for pharmaceutical, pharmacy, and PBM issues, including the launch and operation of the Medicare Prescription
Drug Benefit (Part D). More specifically, he led the development of policy and regulation under the Part D program;
guided CMS efforts to design and develop new systems functionality for providing beneficiary information to
providers in real time at the point of sale, he designed and launched CMS initiatives on pharmacy quality and
pharmacy quality alliances, and he supervised pharmaceutical delivery and data management during and after
Hurricane Katrina.
Prior to joining KPMG, Kocot practiced law at Epstein Becker Green, PC, and Dentons, US LLP. From 2007-2015,
Kocot was a visiting fellow in the Economic Studies Program at the Brookings Institution; he was also Deputy
Director of the Engelberg Center for Health Care Reform at Brookings from 2007-2013. Kocot was a fellow in
International Security Studies at the Center for Strategic and International Studies (CSIS), and an adjunct fellow
at CSIS for several years thereafter. Before his government service, Kocot was Senior Vice President and General
Counsel at the National Association of Chain Drug Stores, where he was responsible for all legal matters and
represented the industry before Congress, state legislatures, and state and federal regulatory agencies.
Pierre Leurent
Chief Executive Officer, President of the Management Board & Founder
Voluntis
Pierre has more than 15 years of international experience in software, medical devices,
disease management, and telemedicine solutions in Europe and the United States. Before
founding Voluntis in 2001, Leurent worked with General Electric Medical Systems and with
HealthCenter Internet Services, an online cardiology EMR solution vendor in San Francisco.
In addition, Leurent is the Director of Syntec Numérique, where he leads the telemedicine
workgroup. He is co-leader of CSIS-CSF’s e-health workgroup and e-health advisor within Nouvelle France
Industrielle’s health steering committee. Leurent is a graduate of the Ecole Centrale Paris engineering school.
Speakers 23
Alan Lotvin
Executive Vice President, CVS/specialty
CVS Health
Dr. Alan M. Lotvin, MD, is Executive Vice President of Specialty Pharmacy for CVS Health.
In this role, Lotvin has overall responsibility for the company’s Specialty Pharmacy business,
a rapidly growing division of the company’s pharmacy benefits management business. He is
focused on driving specialty pharmacy strategy and identifying opportunities for growth and
innovation in this fast-growing segment of the health care industry.
Lotvin is a published author with an extensive clinical background and experience in the health care services,
pharmaceutical benefit management and specialty pharmacy industries. Prior to joining CVS Health, Lotvin was
President and Chief Executive Officer of ICORE Healthcare, a Magellan Health Services company. Previously, he has
held roles as President and Chief Operating Officer of M|C Communications, a leading medical education provider.
After leaving clinical practice, Lotvin served in various senior management roles at Medco Health Solutions,
including serving as President of Medco Specialty Pharmacy Services.
Lotvin began his career as an interventional cardiologist in the New York metropolitan area with a faculty
appointment at College of Physicians and Surgeons at Columbia University. Lotvin holds a Masters Degree in
Medical Informatics from Columbia University and a Medical Degree from the State University of New York Health
Sciences Center in Brooklyn.
Mark Merritt
President & Chief Executive Officer
PCMA
Mark Merritt is the President and Chief Executive Officer of PCMA, which represents the
nation’s PBMs. The PBM industry plays a pivotal role in American health care, administering
prescription drug benefits for over 200 million Americans covered by Fortune 500 companies,
health insurance plans, labor unions, and Medicare Part D.
Before joining PCMA, Merritt played senior roles with America’s Health Insurance Plans
(AHIP), the Pharmaceutical Research and Manufacturers of America (PhRMA), and the presidential campaigns of
Senators Bob Dole and Lamar Alexander.
Merritt also served as a Fellow at Harvard University’s John F. Kennedy School of Government, where he lectured
on the intersection of politics, public policy, and the media. Merritt is known for innovative, campaign-style public
relations strategies that reach beyond Washington to Wall Street, Main Street, even Hollywood.
In 2003, Merritt took the helm of PCMA and quickly bolstered its stature and clout. He is routinely ranked among
the nation’s most effective association executives and is a member of the U.S. Chamber of Commerce’s elite
“Committee of 100.” Recognizing his tireless efforts promoting affordable medicines, the Generic Pharmaceutical
Association (GPhA) selected Merritt for its 2011“Outstanding Contribution” award.
Merritt serves on the Editorial Advisory Board for Drug Benefit News and the Board of The Public Affairs Council,
which represents communications professionals worldwide.
He holds a BA and MA from Georgetown University. He and his wife Jayne have four children.
24 Speakers
Jerry Miller
President
J. Miller Consulting
Jerry Miller, PharmD, is President of J. Miller Consulting, and provides consultative services
to pharmaceutical or biotech companies and other healthcare-related firms. He is a former
Director of Research with Health Strategies Group, specializing in the PBM and managed
markets industry segments. In his twelve years with this firm, he gained recognition as an
industry expert by pharmaceutical manufacturer clients and PBM industry senior leaders.
Miller has a broad background and experience in multiple areas of the profession of pharmacy including hospital,
retail, managed care, Medicaid, and PBMs. His experience includes six years as a member of the pharmacy
administrative staff at Cedars-Sinai Medical Center where he supervised the department’s purchasing, emergency,
and operating room services, and the Pharmacy & Therapeutics Committee. Joining American Stores in 1988, Miller
worked as a Sav-on pharmacy manager, then as the corporate liaison to Cigna of California and Molina Healthcare.
He next joined RxAmerica, now owned by CVS Caremark, serving as Director of Clinical Services for over five years.
Miller received his Doctor of Pharmacy degree from the University of Southern California in Los Angeles.
Betty Nguyen
Anchor and Journalist
NBC News & MSNBC
Betty Nguyen is an award-winning journalist whose work has taken her across the globe. She
is an anchor for NBC News & MSNBC and a correspondent for the Today Show. While at the
network, Nguyen has covered the Ebola outbreak, the Boston Marathon bombings, the election
of Pope Francis, and the birth of Prince George of Cambridge.
Before her move to NBC, she was news anchor for CBS This Morning Saturday, a
correspondent for The Early Show and anchor for the CBS Morning News. There, she covered the 2012 Presidential
election, the death of Osama Bin Laden, the Royal wedding and the Gulf oil spill. Prior to her arrival at CBS,
she anchored the weekend edition of CNN Newsroom, where she contributed to CNN’s award-winning coverage
of Hurricane Katrina and the tsunami disaster in South Asia. She also traveled to Africa to cover the presidential
elections in Sierra Leone, and then to Vietnam to report on deadly flooding in her birth country.
Nguyen has interviewed some of the most important newsmakers and celebrities of our time, including the Dalai
Lama, President George W. Bush, Sir Richard Branson, Charles Barkley, Lenny Kravitz, Willie Nelson, Dolly Parton,
and Usher, just to name a few.
In 2015, she was inducted into the Asian Hall of Fame. She is the recipient of a regional Emmy Award and the
Legacy of Women Award. In 2007, the Smithsonian Institution recognized Nguyen as the first Vietnamese-American
to anchor a national network news program in the United States.
Nguyen also spends her time doing humanitarian work. She is the co-founder of Help the Hungry, a non-profit
organization that strives to alleviate global hunger by providing humanitarian aid to poverty-stricken families. Her
philanthropy work has earned her a spot in the Philanthropy in Texas Hall of Fame.
Speakers 25
Kent Rogers
Senior Vice President, Industry Relations
OptumRx
Kent Rogers currently serves as the Senior Vice President, Industry Relations for OptumRx
with responsibility for formulary and procurement contracting for all books of business on
behalf of internal and external clients of United Health Group. OptumRx is the pharmacy
benefit management division of Optum servicing over 66 million members and processing over
1 billion pharmacy claims which represent over $80 billion in drug spend.
Rogers has more than 25 years of experience with the pharmaceutical industry, focusing primarily on payer, channel
and patient services strategies. Prior to OptumRx, he was a Principal Consultant with Blue Fin Group, served as the
Vice President of Managed Markets at Acorda Therapeutics, and held various positions of increasing responsibility
within Sales and Managed Markets at Schering Plough and Merck. His career experience includes business
development, health economics/outcomes research, building and leading market access teams, developing and
implementing payer access and channel strategies, and launching patient services programs.
Rogers has a Bachelor of Science in Business Management from Indiana University, and an MBA from Emory
University’s Goizueta School of Business.
Bill Roth
Founding Partner
Blue Fin Group
Bill Roth is serial entrepreneur and a tenured corporate executive. As Founding Partner of
Blue Fin Group, a management consultancy for the pharmaceutical industry, Roth started
the company in 2001 and has grown the organization to service most manufacturers and a
wide array of channels and service providers. He is considered an innovator and an expert in
connecting health care products to patient populations. Roth has consistently forecasted future
events in the industry, and he has led his clients and companies to successful outcomes for more than 25 years.
Roth has been quoted in dozens of industry publications. He is repeatedly cited by market researchers, analysts,
and industry leaders for his accurate predictions, and he speaks frequently at industry events and seminars on the
subject of commercialization and related issues. Roth’s unique breadth of experience and knowledge from working
with all models in the health care industry provides great context when working to solve challenging business
puzzles in our industry.
Roth was featured as the cover story of Pharmaceutical Commerce in January 2016 and was featured in
Entrepreneur Magazine in 2001. He is also a 2008 recipient of PharmaVOICE magazine’s “Top 100 most-inspiring
people in Life Sciences” and was named a 2009 “People to Watch” by PM360 Magazine.
26 Speakers
Mike Ryan
Senior Vice President, U.S. Value, Access and Policy
Bristol-Myers Squibb
Dr. Michael L. Ryan, PharmD, is the Senior Vice President for U.S. Value, Access and Policy
for Bristol-Myers Squibb. In this role, Ryan is responsible for all pricing, contracting, payer
strategy, value and access marketing, and policy across the $8B U.S. BMS portfolio, as well
as all field reimbursement strategy, and execution across all U.S. payers.
Prior to joining Bristol-Myers Squibb, Ryan spent 16 years at Amgen as the Vice President and
General Manager for U.S. Reimbursement, Value and Access, where he was responsible for all pricing, contracting,
government price reporting, payer strategy, and value and access marketing across the $13B U.S. Amgen portfolio.
He also served as the Vice President and General Manager of the nephrology business unit for Amgen, where he was
responsible for the P&L and life cycle management of Amgen’s three products used to treat patients with kidney
disease; Epogen®, Aranesp® and Sensipar®.
Other roles that Ryan held at Amgen include Vice President and General Manager of Corporate Accounts, where he
was responsible for Amgen’s largest corporate customer groups including managed care, integrated health systems,
commercial and government payers, group purchasing organizations, pricing, and distribution channels, and he was
Senior Director of Central Reimbursement where he was responsible for the analysis and development of legislative
and reimbursement strategies across the Amgen portfolio, as well as directing the implementation of such strategies
through Amgen’s Government Economics Management sales force. Ryan first joined Amgen in 1999, as Director of
Information, Healthcare Economics, and Pharmacy Affairs.
Prior to Amgen, Ryan served as Associate Professor and Chairman, Department of Pharmacy and Therapeutics,
University of Pittsburgh School of Pharmacy, and Executive Director, Department of Pharmacy, and Director,
Clinical Information System Implementation, The University of Pittsburgh Medical Center. Ryan also served
as President and Executive Director of Community Pharmacy Services Corporation and H.C. Pharmacy, Inc., a
University of Pittsburgh Medical Center owned and operated for-profit business and drug wholesaler and distributor.
During his tenure at the University of Pittsburgh, Ryan also held affiliated faculty appointments with both the
Department of Clinical Pharmacology and the Center for Biomedical Informatics.
Ryan is a graduate of the University of California at Los Angeles (1976) and the University of California at San
Francisco (1980), and he completed his residency program at the University of Michigan Hospitals and College of
Pharmacy in 1981. After completing his residency, Ryan continued to work with the University of Michigan College
of Pharmacy and the University of Michigan Medical Center for 15 years.
During his career, Ryan has been invited to present over 100 national platform presentations, and he has over
30 refereed journal and textbook publications. The primary focus of Ryan’s research is pharmacoeconomics,
pharmacoinformatics, healthcare policy, drug use and disease state management, and the application of Total
Quality Management principals to a health care environment. Among his many and varied responsibilities, Ryan
has served on numerous national health care committees, directed and/or participated on over 12 Pharmacy and
Therapeutics Committees, implemented seven for-profit businesses, developed numerous novel and innovative
pharmacy services, directed the implementation of five pharmacy computer systems and the Cerner Millennium
Clinical Information System, developed numerous pharmacoinformatic decision support programs, and served
as a professor at both the University of Pittsburgh and University of Michigan Schools of Pharmacy and Medical
Informatics Training Programs.
Speakers 27
George Scangos
Chief Executive Officer
Biogen
George A. Scangos, PhD, is the Chief Executive Officer of Biogen. He has served in this
position and as a member of our Board of Directors since July 2010.
From 1996 to July 2010, Scangos served as the President and Chief Executive Officer of
Exelixis, Inc., a drug discovery and development company, where he continues to serve on the
board. From 1993 to 1996, Scangos served as President of Bayer Biotechnology, where he
was responsible for research, business development, process development, manufacturing, engineering, and quality
assurance of Bayer’s biological products. Before joining Bayer in 1987, Scangos was a professor of biology at Johns
Hopkins University for six years, where he is still an adjunct professor. Scangos served as non-executive Chairman
of Anadys Pharmaceuticals, Inc., a biopharmaceutical company, from 2005 to July 2010 and was a director of the
company from 2003 to July 2010. He also served as the Chair of the California Healthcare Institute in 2010 and
was a member of the board of the Global Alliance for TB Drug Development until 2010.
Scangos is Chairman of the Board of Directors of Pharmaceutical Research and Manufacturers of America (PhRMA),
a member of the Boards of Trustees of the Boston Museum of Science and the Biomedical Science Careers
Program, and a member of the National Board of Visitors of the University of California, Davis School of Medicine.
Scangos is also on the Board of Directors of Agilent Technologies, Inc., a provider of bioanalytical and electronic
measurement solutions.
Tim Wentworth
President & Chief Executive Officer
Express Scripts
Tim Wentworth, President and Chief Executive Officer of Express Scripts, is responsible for
ensuring Express Scripts delivers on its mission to put medicine within reach of people who
need it. Express Scripts is the country’s leading pharmacy benefit manager with 27,000
employees responsible for 1.3 billion annual prescriptions for 3,000 clients and 85 million
people.
Wentworth joined Express Scripts in 2012 as senior vice president and president, sales and account management.
He was promoted to president of the company in 2014, elected to the Board of Directors in January 2015, and
became CEO in May 2016.
Prior to joining the company, he led the employer and key accounts organizations at Medco Health Solutions for
nearly 14 years. In 2006, Wentworth became president and CEO of Accredo specialty pharmacy, leading the rapid
and successful integration of Accredo into the broader Medco organization.
Before Medco, Wentworth spent five years at Mary Kay, Inc., where he served initially as senior vice president
of human resources and subsequently as president, international. He also spent nine years in human resources
management at PepsiCo.
A well-respected leader in his field, Wentworth has been a featured speaker at Harvard University, the Health
Evolution Summit, the American Management Association, and the Best 100 Companies Symposium, among
other events. He is a Trustee of the University of Rochester (NY), serving on the Health Strategy and Personnel
Committees.
Wentworth received his associate’s degree from Monroe Community College and a Bachelor of Science degree in
Industrial and Labor Relations from Cornell University.
28 Speakers
ABOUT PCMA
About PCMA
PCMA Board of Directors
Chairman, PCMA Board of Directors
Vice Chairman and Incoming Chairman
Tim Wentworth
President & Chief Executive Officer
Express Scripts
William Fleming
Segment Vice President, Humana Inc.
President, Humana Pharmacy Solutions
Jim DuCharme
President & Chief
Executive Officer
Prime Therapeutics
Chris Hocevar
President, Select
Segment & Cigna
Pharmacy Management
Cigna Corporation
Mark Thierer
Chief Executive Officer
OptumRx
Mostafa Kamal
Chief Executive Officer
Magellan Rx Management
Greg Watanabe
President
MedImpact
Jon Roberts
President
CVS/caremark
& Executive Vice
President
CVS Health
Bill Wolfe
Vice President, Pharmacy
Aetna
PCMA Board of Directors 29
PCMA Staff
Mark Merritt
President & Chief Executive Officer
April Alexander
Senior Director, State Affairs
Wendy Krasner
Vice President, Regulatory Affairs
Kristin Bass
Senior Vice President, Policy and Federal Affairs
Barbara Levy
General Counsel
Tim Brogan
Vice President, Research
Greg Lopes
Senior Director, Strategic Communications
Megan Coder, PharmD
Senior Director, Industry Programs
Jessica Mazer, Esq
Assistant Vice President, State Affairs
Andy Cosgrove
Vice President, Policy
Brian McCarthy
Chief Operating Officer
Charles Coté
Vice President, Strategic Communications
Anne McCraw
Assistant Vice President, Industry Relations
Jenny Dawson
Senior Manager, Conferences and Development
Casey Murphy
Senior Director, Federal Affairs
Jonathan Heafitz
Assistant Vice President, Federal Affairs
Brenda Palmer
Chief Financial Officer
Ryan Hickey
Senior Director, Accounting and Operations
Kristen Pumphrey
Senior Director, Conferences
Greg Johnson
Vice President, Strategic Initiatives
Meagan Riordan
Director, State Affairs
Jennifer Joslin
Executive Assistant to the President & CEO
Deloris Tinsley
Executive Assistant
Scott Kipper
Vice President, State Affairs
Scott Woods
Senior Director, Policy
30 PCMA Staff
PCMA Members
PCMA Members 31
2016 PCMA Affiliates
32 2016 PCMA Affiliates
MARKETPLACE
Marketplace
Conference Sponsors
PARTN ER S
P R E SID EN TIAL SPO N SO R S
E X ECU TIVE SPO N SO R S
G EN ER AL SPO N SO R S
Changing Tomorrow,
Together
At Astellas, we believe we can make a real impact on the future.
That’s why we are fully committed to developing medicines
that make a difference where they’re needed most, in
areas like oncology, urology, cardiology and transplant.
It’s also why we focus on bringing together a diverse
group of people with a common goal: to help transform
lives. Whether it’s in the office, the laboratory or the
community, we’re working together to change
tomorrow.
@AstellasUS
www.astellas.us
080-1021-PM
Caring deeply about those around us
We know that living with multiple sclerosis (MS) can present some pretty
large challenges. At Biogen™, we are committed to patients through
ongoing research and support services to help meet unmet needs in
the management of MS.
Visit Biogen.com, or call 1 800 456 2255.
© 2015 Biogen. All rights reserved. 09/15 FCH-US-0947
Otezla® is a registered trademark of Celgene Corporation.
© 2016 Celgene Corporation 08/16 USII-APR150131(1)a
44120_ceusps_reminder_ad_resize_fi.indd 1
8/17/16 2:25 PM
TURGUT AKMETE
Turgut has type 2 diabetes
For nearly a century, we have been committed to ending diabetes. And as a leader in
research, education, and unique partnerships, we do it for all the patients like Turgut, who
never lose hope for a future free from their disease. And that’s why we believe that together
we can defeat diabetes in our lifetime. For more about us, visit novonordisk-us.com.
© 2012 Novo Nordisk Printed in the U.S.A. 0712-00010441-1 October 2012
We Make Quality
Healthcare Accessible
Teva Pharmaceuticals is working every day to make
quality healthcare accessible around the world.
As a manufacturer of specialty and generic
pharmaceuticals, Teva provides both new therapies
and greater access to quality, affordable medicines.
tevausa.com
SOLVING THE
WORLD’S TOUGHEST
HEALTH CHALLENGES
TAKES ALL OF US.
It takes the will to find a new way forward.
And no one gets there alone.
That’s why AbbVie teams with peers,
academics, clinical experts, and our partners in
managed care and specialty pharmacy to take
on the most complex health challenges.
Uniting the best of pharma with the boldness
of biotech, together we’re going beyond
conventional thinking to innovate end-to-end
approaches that make a real difference.
We start with science and work with our
colleagues in healthcare to arrive at solutions
that help millions of patients live better.
abbvie.com
BOLD
FOR
LIFE
We are a bold, global pharmaceutical
company and a leader in a new industry
model – Growth Pharma. Our worldclass team develops, manufactures and
commercializes innovative branded
pharmaceuticals and biologic products
for patients around the world.
We are one team of dedicated employees,
carving new paths, taking bold, decisive
actions to deliver results and better
outcomes for patients and providers.
www.Allergan.com
78479-R1-V1
What
science
can do
Advancing Quality of Patient Care
At AstraZeneca, we know improving
the lives of patients requires
engagement across all of healthcare,
and we are committed to pursuing
innovative collaborations that
advance quality of care, improve
patient outcomes and deliver value
to the healthcare system.
We also work to support meaningful
access to our medicines and
actively engage patients in
their own care along with their
healthcare professionals to help
slow progression of disease,
reduce readmissions, and decrease
complications.
To learn more about how
AstraZeneca is pushing the
boundaries of science to deliver
life-changing medicines,
transforming serious diseases like
cancer, heart disease, diabetes, and
asthma, visit astrazeneca-us.com.
Oncology combination therapies
AstraZeneca is investigating combinations
of biologic and small-molecule therapies for
the treatment of cancer. These combinations
target the tumor directly and some help
boost the body’s own immune system to
potentially induce cell death.
© 2015 AstraZeneca. All rights reserved. 3133005 5/15
At Bayer we encourage you to question
the status quo and constantly think
beyond the obvious. We foster open
discussions, sharing knowledge across
our community and partnering with
external networks. We always start by
listening – because our customers are at
the heart of everything we do. At Bayer
you have the opportunity to be part of a
culture where we value the passion of
our employees to innovate and give
them the power to change.
Passion to innovate | Power to change
EB Ad 7.5x10.indd 1
8/18/16 2:46 PM
Nurturing innovative ideas today
for more health tomorrow.
Boehringer Ingelheim ranks among the world’s 20 leading
pharmaceutical corporations. Our vision drives us forward.
It helps us to foster value through innovation in our
company and to look to the future with constantly renewed
commitment and ambition.
For more than 125 years, Boehringer Ingelheim has been
committed to the research and development of innovative
medicines that help make more health for patients and
their families.
Visit us online at
us.boehringer-ingelheim.com
Imagine what you could build using
the nation’s largest electronic prior
authorization network.
500+
INTEGRATED EHRs
PAYERS REPRESENTING
75%
OF U.S. RX VOLUME
600,000+ PROVIDERS
NEARLY 48,000
PHARMACIES
80%
OF PHARMACY MARKET
CoverMyMeds integrates directly into the clinical workflow.
covermymeds.com • 1-866-452-5017
access
ONCOLOGY
SPECIALTY DIGEST
PATIENT ADHERENCE
PARTNERSHIPS
MARKET INSIGHTS
NEUROLOGY
SECURE DISTRIBUTION
PATIENT SUPPORT
PROGRAMS
PARTNERSHIPS
FERTILITY/
ENDOCRINOLOGY
NATIONAL/LOCAL SUPPORT
©2016 EMD Serono, Inc. US-MLT-0316-0002
We believe in more than the big
breakthroughs. And more than the next
big thing.
We believe in the day-in day-out work of
making science happen. And the millions
of little victories — and failures — in
between the breakthroughs. Because to
us, it’s the daily effort of everyday people
that changes the future. So we don’t
stop. We keep working. Every day.
Jacki, patient
Advancing
Therapeutics,
Improving
Lives.
For more than 25 years, Gilead has worked
to develop medicines that address areas
of unmet medical need for people around
the world.
Our portfolio of medicines and pipeline of
investigational drugs include treatments
for HIV/AIDS, liver diseases, cancer and
inflammation, and serious respiratory and
cardiovascular conditions.
Every day we strive to transform and simplify
care for people with life-threatening illnesses.
For more information, please visit www.gilead.com.
© 2015 Gilead Sciences, Inc.
But in order to fully achieve our mission of helping people do more, feel better
and live longer, we need to go beyond discovering, developing and delivering
new medicines, vaccines and healthcare products. That’s why we support
innovative health and education programs designed to bring sustainable,
positive change in local communities across America.
© 2001– 2016 GLAXOSMITHKLINE ALL RIGHTS RESERVED.
Every challenge creates opportunity
Every relationship brings responsibility
Providing services for Janssen Pharmaceutical Companies of Johnson & Johnson
Every patient is
our inspiration
© Johnson & Johnson Health Care Systems Inc. 2015
February 2015
027922-150115
Hong Hu, Research Advisor,
Lilly Research Laboratories
It begins with a promise
to discover medicines that make life better.
Since 1876, we have worked tirelessly to develop and deliver trusted medicines that
meet real needs, finding ways to come through no matter the odds. From the
development of insulin to the discovery of new treatments for mental illness,
we have pioneered breakthroughs against some of the most stubborn and
devastating diseases. We bring this same determination to our work today,
uniting our expertise with the creativity of research partners across the
globe to keep finding ways to make life better.
To find out more about our promise, visit www.lilly.com/about.
2016 CA Approved for External Use PRINTED IN USA ©2016, Eli Lilly and Company. ALL RIGHTS RESERVED.
Navigating the path to
medication access
Novartis Oncology is committed to helping patients living with cancer receive the
medicines they need. Patient Assistance Now Oncology (PANO) offers quick
and easy access to information about our wide range of resources.
SUPPORT FOR PATIENTS INCLUDES:
• Support with insurance verification
• Medicare education
• Alternative assistance searches
and referrals to federal or state
assistance programs
• Support for Novartis Oncology
medication
• Patients prequalified via phone
screening for the Patient
Assistance Program (PAP) will
be sent a 30-day supply of
their needed medication while
completing the application
• Information about financial
or co-pay assistance that may
be available via independent
charitable foundations
GET ACCESS NOW
Visit www.OncologyAccessNow.com/patient, or call 1-800-282-7630, to speak with a member of our knowledgeable
staff dedicated to making access to therapy as simple and convenient as possible.
Novartis Pharmaceuticals Corporation
East Hanover, New Jersey 07936-1080
© 2015 Novartis
10/15
T-PAN-1125452
18,000
More than
employees in the United States
A comprehensive offering of
medicines, vaccines and
innovative services all over
the world
120
© Blue Images/Corbis - ooyoo/getty images
More than
locations
across North America
SANOFI FOCUSED ON PATIENTS’NEEDS
Over the years, Sanofi has evolved to meet the new challenges of healthcare worldwide.
Today, Sanofi is a global healthcare leader focused on patients. We listen to their needs, treat
them, and provide support to them. Through our diversified portfolio of medicines, vaccines
and innovative therapeutic solutions, we strive to protect the health and meet the needs of the
world’s 7 billion people.
US.COR.14.06.005
For more information: www.sanofi.com – www.sanofi.us
www.facebook.com/sanofiUS
www.twitter.com/sanofiUS
www.pinterest.com/sanofiUS
blog.sanofi.us
T:7.5”
T:10”
UNMET NEEDS REQUIRE
UNMATCHED COMMITMENT.
The combined talents and energy of Shire and Baxalta are uniting in
common cause: to make a difference in the lives of those living with
and affected by rare diseases and highly specialized conditions.
For more information, please visit shire.com
INTSP/C-ANPROM/CORP/16/0022
S13862 05/16
Sunovion supports PCMA in its
mission to promote industry relations
and thought leadership throughout
the pharmaceutical supply chain
A proud sponsor of the 2016 PCMA Annual Meeting,
Sunovion is a global biopharmaceutical company
focused on the innovative application of science
and medicine to help people with serious medical
conditions. Our spirit of innovation is driven by the
conviction that scientific excellence paired with
meaningful advocacy and relevant education can
improve lives.
Visit us at www.sunovion.com
and connect with us on Twitter @Sunovion
and LinkedIn.
Working in Partnership with You
We’re driven to improve people’s lives.
Takeda strives toward better health for people
worldwide through leading innovation in medicine.
At Takeda, we make a commitment to make a difference.
Takeda Pharmaceuticals U.S.A., Inc.
www.takeda.us
USD/TAK/15/0042i
THE SCIENCE of POSSIBILITY
Vertex creates new possibilities in medicine to cure
diseases and improve people’s lives.
We work with leading researchers, doctors, public health experts
and other collaborators who share our vision for transforming the
lives of people with serious diseases, their families and society.
www.vrtx.com
© 2016 Vertex Pharmaceuticals Incorporated
CONTINUING
OUR
COMMITMENT
TO PAH
Actelion Pharmaceuticals is proud to support the
Pulmonary Hypertension Association in advancing
the treatment and care of patients with PAH.
© 2015 Actelion Pharmaceuticals US, Inc. All rights reserved. ACT-00747 0315
FOCUSED ON DEVELOPING SPECIALTY TREATMENTS
for debilitating diseases that are often difficult to diagnose
and treat, providing hope to patients and their families.
www.sanofigenzyme.com
Lundbeck is a pharmaceutical company committed to
improving the lives of those suffering from psychiatric
and neurological disorders.
We support and participate in hundreds of community awareness
and educational events each year. This participation fuels our passion
to make a difference, one patient at a time.
To learn more about Lundbeck, visit www.lundbeckus.com.
UBR-D-00077
SEEING COMPLEXITY
IN A NEW LIGHT.
For nearly 150 years, Mallinckrodt has made
complex scientific problems manageable,
developing valuable treatments and diagnostic
tools for patients who need them.
Learn more at Mallinckrodt.com
Mallinckrodt, the “M” brand mark and the Mallinckrodt Pharmaceuticals logo are trademarks of
a Mallinckrodt company. © 2016 Mallinckrodt. July 2016
Welcome to Scottsdale, elevation 1,150 to 4,877 feet
At Medivation, we strive to
transform and elevate patients’
lives with our medically
innovative therapies
To ensure patients have access to our medical solutions, we
partner with a network of specialty pharmacies and provide
educational resources with every prescription delivery.
Contact a National Account Director for more information
or visit medivation.com.
A proud supporter of the PCMA
©2016
rights reserved.
reserved. Printed
Printed in
in USA.
USA. XXX-XXX-XX-XXXX
CCM-MDV-US-0023
7/16
©2016 Medivation,
Medivation, Inc.
Inc. All
All rights
12/15
MEDICAL BREAKTHROUGHS MAY COME OUT OF THE LAB.
BUT THEY BEGIN IN THE HEART.
For more than 150 years, a very special passion has driven the people of Merck. Our goal is to develop
medicines, vaccines, consumer care and animal health innovations that will improve the lives of millions.
Still, we know there is much more to be done. And we’re doing it, with a long-standing commitment to
research and development. We’re just as committed to expanding access
to healthcare and working with others who share our passion to create a
healthier world. Together, we’ll meet that challenge. With all our heart.
For more information about getting Merck medicines and vaccines for free, visit merckhelps.com or call 800-727-5400.
Copyright © 2013 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. All Rights Reserved. CORP-1060080-0006 01/13
MerckAd_Lab_Half_Clr.indd 1
2/5/13 10:24 AM
Mylan believes we
all share one wish
– to go where our
dreams take us.
At Mylan, we’re committed to
helping people live their dreams
by providing access to high quality
medicine for the world’s 7 billion
people, one person at a time.
Mylan.com
August 2016 01US16EUC0093
The development of opioids formulated to
deter abuse is a high public health priority.1
Visit TeamAgainstOpioidAbuse.com
Reference: 1. Food and Drug Administration, Center for Drug Evaluation and Research (CDER), US Department of Health and Human
Services. Abuse-Deterrent Opioids — Evaluation and Labeling: Guidance for Industry. April 2015. http://www.fda.gov/downloads/
drugs/guidancecomplianceregulatoryinformation/guidances/ucm334743.pdf. Accessed August 17, 2016.
©2016 Purdue Pharma L.P., Stamford, CT 06901-3431 MR-02050 B10211-PCMA 8/16
Valeant Pharmaceuticals
International, Inc. is
committed to innovation
and to improving
people’s lives through its
healthcare products.
W W W.VA L E A N T.C OM
Acorda’s mission is to develop therapies that restore function and improve
the lives of people with neurological disorders. We are proud to be a sponsor
of the Pharmaceutical Care Management Association’s Annual Meeting.
www.acorda.com
The stylized Acorda logo is a trademark of Acorda Therapeutics, Inc.
© 2015 Acorda Therapeutics, Inc. All rights reserved. 8/15 MS3735
We Understand Your Challenges.
We Are Committed to Seeking Solutions.
We are dedicated to developing therapies and navigating
treatment management challenges to help payers, providers
and patients address the burden of CNS diseases.
A global biopharmaceutical company with fully integrated R&D,
manufacturing and commercial capabilities in the U.S.
For more information, reach out to your Alkermes
Account Director or visit us at www.alkermes.com
©2016 Alkermes. All Rights Reserved. OT-001345
At Bristol-Myers Squibb, we are
working together for patients.
Our mission is clear — we discover,
develop and deliver transformational
medicines that help people prevail
over serious diseases.
Our sense of urgency is real — we work
every day to push the boundaries
of scientific discovery and to make
a meaningful difference in the lives
of patients.
It’s what we do. It’s why we do it.
www.bms.com
© 2016 Bristol-Myers Squibb Company
Ingenuity in Medicine
Visit collegiumpharma.com for more information
© 2016 Collegium Pharmaceutical, Inc. All rights reserved. PP-CORP-US-0016 8/16
1607066_PCMA-Ad-082516-v5.indd 1
8/26/16 1:46 PM
Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address
diversified, unmet medical needs of patients in both mature and emerging markets.
With over 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 16,000
employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines
to help people. In addition to a strong portfolio of medicines for hypertension and thrombotic disorders, under
the Group’s 2025 Vision to become a “Global Pharma Innovator with a Competitive Advantage in Oncology,”
Daiichi Sankyo research and development is primarily focused on bringing forth novel therapies in oncology,
including immuno-oncology, with additional focus on new horizon areas, such as pain management, neurodegenerative
diseases, heart and kidney diseases, and other rare diseases.
For more information, please visit: www.daiichisankyo.com. Daiichi Sankyo, Inc., headquartered in Parsippany,
New Jersey, is a member of the Daiichi Sankyo Group. To learn more about Daiichi Sankyo, Inc., visit www.dsi.com.
DSNA16102716
Half-page-no-bleed-horizontal-color-b.indd 6
08/16
8/11/16 3:26 PM
Introducing the World’s First
Continuous Glucose Monitoring (CGM)
System on the Phone
See glucose in a
whole new way with
Dexcom G5®
Mobile CGM
System*
CGM reveals what no meter can. Unlike fingersticks
that give a number for a single point in time,
CGM lets you see your glucose in real time so you’ll
always know when your glucose is trending
high, low or when you’re good to go.**
With Dexcom G5 Mobile CGM System, viewing your
data is easier than ever. With glucose information
displayed directly onto your smart phone,*** you’ll get
the ultimate in convenience and discretion.
Always know with Dexcom G5 Mobile CGM System.
To learn more, visit dexcom.com/G5Mobile.
BRIEF SAFETY STATEMENT
The Dexcom G5 Mobile Continuous Glucose Monitoring System (the “System”) is a glucose monitoring system indicated for detecting trends and tracking patterns in persons (age 2 years and older) with diabetes. CONTRAINDICATIONS Remove the System (sensor, transmitter, and receiver) before Magnetic Resonance Imaging (MRI), Computed Tomography (CT) scan, or high-frequency
electrical heat (diathermy) treatment. The System is MR Unsafe. Do not bring any portion of the System into the MR environment. Taking acetaminophen while wearing the sensor may falsely raise your sensor glucose readings. WARNING Do not use the System for treatment decisions. The System does not replace a blood glucose meter. The System is not approved for use in pregnant
women, persons on dialysis or critically ill persons. If a sensor breaks and no portion of it is visible above the skin, do not attempt to remove it. Seek professional medical help if you have infection or inflammation. Report broken sensors to Dexcom Technical Support. Sensor placement is not approved for sites other than under the skin of the belly (ages 2 years and older) or upper buttocks
(ages 2-17 years). Your smart device’s internal settings override your Dexcom app settings. Accessory devices (like a smart watch) might override your smart device’s alert and notification settings. The Share feature must be turned “On” with an active internet connection to communicate glucose information to a Follower. The Follower must download and install the Dexcom Follow App
onto a separate smart device with an active internet connection to receive data. Contact Dexcom Toll Free at 877-339-2664 or www.dexcom.com for detailed indications for use and safety information.
* Dexcom G5 Mobile Continuous Glucose Monitoring System, User’s Guide, 2015. ** The Dexcom G5 Mobile CGM System does not replace a blood glucose meter. Always use the values from your blood glucose meter for treatment decisions. *** To view a list of compatible devices, visit www.dexcom.com/compatibility
LBL013625 Rev002
©2016 Dexcom Inc. All rights reserved.
Passionate about
patient care
Eisai’s passionate commitment to patient care
is the driving force behind our efforts to find
innovative solutions that help address unmet
medical needs and contribute to the wellbeing of patients worldwide. With therapies
in oncology and specialty care, we focus on
having an impact on patients and their families.
At Eisai, human health care is our goal.
CORP-US0023
©2016 Eisai Inc.
All rights reserved.
Aug 2015
www.eisai.com/us
Improving Lives,Creating Value.
TM
At Endo International, our specialty branded pharmaceuticals,
generic products and over-the-counter medications play an important
role in helping millions of patients lead healthier lives. Through our operating
companies, we are dedicated to serving our patients, customers and shareholders
as we continually search for new and better ways to do things while creating value.
www.endo.com
© 2016 Endo. All Rights Reserved.
Help your new-to-dialysis patients succeed with Velphoro
Start with high potency. Stay with long-term control.*
1
Long-term efficacy with a low pill burden†1,2
Long-term tolerability as demonstrated
in the 52-week study†1,2
Access and affordability for most patients
VISIT VELPHORO.COM/HCP
TO DOWNLOAD $0 CO-PAY SAVINGS CARDS
AND OTHER RESOURCES.
*Clinical results of individual patients from long-term trial.
INDICATION
Velphoro® (sucroferric oxyhydroxide) is a phosphate binder
indicated for the control of serum phosphorus levels in patients
with chronic kidney disease on dialysis.
IMPORTANT SAFETY INFORMATION
• Velphoro must be administered with meals. Velphoro tablets
must be chewed and not swallowed whole. To aid with
chewing and swallowing, the tablets may be crushed.
• Patients with peritonitis during peritoneal dialysis, significant
gastric or hepatic disorders, following major gastrointestinal
(GI) surgery, or with a history of hemochromatosis or other
diseases with iron accumulation have not been included
in clinical studies with Velphoro. Monitor effect and iron
homeostasis in such patients.
• In a parallel design, fixed-dose study of 6 weeks duration,
the most common adverse drug reactions to Velphoro
chewable tablets in hemodialysis patients included discolored
feces (12%) and diarrhea (6%).
• Velphoro can be administered concomitantly with oral
calcitriol, ciprofloxacin, digoxin, enalapril, furosemide, HMG
CoA reductase inhibitors, hydrochlorothiazide, losartan,
metoprolol, nifedipine, omeprazole, quinidine and warfarin.
Take doxycycline at least 1 hour before Velphoro. Velphoro
should not be prescribed with oral levothyroxine.
Please see Brief Summary on adjacent page or visit
www.Velphoro.com for full Prescribing Information.
A 52-week, open-label, active-controlled, phase 3 study evaluated the safety and efficacy of
Velphoro in lowering serum phosphorus levels in patients (N=1,054) with chronic kidney disease
on hemodialysis or peritoneal dialysis.1
†
References: 1. Velphoro® [package insert]. Waltham, MA: Fresenius Medical Care North America;
2014. 2. Floege J, Covic AC, Ketteler M, et al; on behalf of the Sucroferric Oxyhydroxide Study Group.
Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients.
Nephrol Dial Transplant. 2015;30(6):1037-1046.
Velphoro is a registered trademark of Vifor Fresenius Medical Care Renal Pharma Ltd.
Distributed by: Fresenius Medical Care North America
Waltham, MA 02451
© 2016 Fresenius Medical Care, all rights reserved. PN 102983-01 Rev. A 03/2016
Brief Summary:
Please see Full Prescribing Information for additional information
seen in animal studies with doses up to 16 times the maximum
recommended clinical dose on a body weight basis. The effects
of Velphoro on labor and delivery in humans are not known.
Nursing Mothers
Since the absorption of iron from Velphoro is minimal, excretion
of Velphoro in breast milk is unlikely.
INDICATIONS AND USAGE
Velphoro (sucroferric oxyhydroxide) is a phosphate binder indicated
for the control of serum phosphorus levels in patients with chronic
kidney disease on dialysis.
DOSAGE AND ADMINISTRATION
Velphoro tablets must be chewed and not swallowed whole. To aid
with chewing and swallowing, tablets may be crushed.
The recommended starting dose of Velphoro is 3 tablets (1,500 mg)
per day, administered as 1 tablet (500 mg) 3 times daily with meals.
Adjust by 1 tablet per day as needed until an acceptable serum
phosphorus level is reached, with regular monitoring afterwards.
Titrate as often as weekly.
DOSAGE FORMS AND STRENGTHS
Velphoro (sucroferric oxyhydroxide) chewable tablet 500 mg.
CONTRAINDICATIONS
None.
WARNINGS AND PRECAUTIONS
Pediatric Use
The safety and efficacy of Velphoro have not been established
in pediatric patients.
Geriatric Use
Of the total number of subjects in two active-controlled clinical
studies of Velphoro (N=835), 29.7% (n=248) were 65 and over.
No overall differences in safety or effectiveness were observed
between these subjects and younger subjects.
OVERDOSAGE
There are no reports of overdosage with Velphoro in patients. Since
the absorption of iron from Velphoro is low, the risk of systemic iron
toxicity is low. Hypophosphatemia should be treated by
standard clinical practice.
Velphoro has been studied in doses up to 3,000 mg per day.
HOW SUPPLIED/STORAGE AND HANDLING
Velphoro are chewable tablets supplied as brown, circular, bi-planar
tablets, embossed with “PA 500” on 1 side. Each tablet of Velphoro
contains 500 mg iron as sucroferric oxyhydroxide. Velphoro tablets
are packaged as follows:
NDC 49230-645-51
Bottle of 90 chewable tablets
Patients with peritonitis during peritoneal dialysis, significant gastric
or hepatic disorders, following major gastrointestinal surgery,
or with a history of hemochromatosis or other diseases with iron
accumulation have not been included in clinical studies with
Velphoro. Monitor effect and iron homeostasis in such patients.
Storage
Store in the original package and keep the bottle tightly closed in
order to protect from moisture.
Store at 25°C (77°F) with excursions permitted to 15 to 30°C
(59 to 86°F).
ADVERSE REACTIONS
PATIENT COUNSELING INFORMATION
In a parallel design, fixed-dose study of 6 weeks duration, the
most common adverse drug reactions to Velphoro chewable
tablets in hemodialysis patients included discolored feces (12%)
and diarrhea (6%).
To report SUSPECTED ADVERSE REACTIONS, contact Fresenius
Medical Care North America at 1-800-323-5188 or FDA at
1-800-FDA-1088 or www.fda.gov/medwatch.
DRUG INTERACTIONS
Velphoro can be administered concomitantly with oral calcitriol,
ciprofloxacin, digoxin, enalapril, furosemide, HMG-CoA reductase
inhibitors, hydrochlorothiazide, losartan, metoprolol, nifedipine,
omeprazole, quinidine and warfarin.
Take doxycycline at least 1 hour before Velphoro.
Velphoro should not be prescribed with oral levothyroxine.
USE IN SPECIFIC POPULATIONS
Pregnancy
Pregnancy Category B: Reproduction studies have been performed
in rats and rabbits at doses up to 16 and 4 times, respectively, the
human maximum recommended clinical dose on a body weight
basis, and have not revealed evidence of impaired fertility or harm
to the fetus due to Velphoro. However, Velphoro at a dose up
to 16 times the maximum clinical dose was associated with
an increase in post-implantation loss in pregnant rats. Animal
reproduction studies are not always predictive of human response.
There are no adequate and well-controlled studies in pregnant
women.
Labor and Delivery
No Velphoro treatment-related effects on labor and delivery were
Inform patients that Velphoro tablets must be chewed and not
swallowed whole. To aid with chewing and swallowing, the tablets
may be crushed [see Dosage and Administration].
Velphoro should be taken with meals.
Instruct patients on concomitant medications that should be dosed
apart from Velphoro [see Drug Interactions].
Inform patients that Velphoro can cause discolored (black) stool.
Distributed by:
Fresenius Medical Care North America
920 Winter Street
Waltham, MA 02451
US Patent Nos. 6174442 and pending, comparable and/or related patents.
© 2014 Fresenius Medical Care North America. All rights reserved.
MORE THAN
75 YEARS
OF IMPROVING
THE HEALTH &
WELL-BEING OF
PEOPLE WORLDWIDE
At Grifols, we are proud of our pioneering spirit and history of innovation.
In 1940, we founded a company that has helped transform hematology.
Learn more about Grifols at
www.grifols.com
Ad_PCMA_16.indd 1
US/CO/0116/0049
Today, we are a global leader providing life-saving protein therapies,
diagnostic solutions, and other tools that hospitals, pharmacies, and
healthcare professionals need to deliver expert medical care.
14/7/16 8:23
Trim: 7.5”
Live: 7”
A legacy of trust.
A future of care.
© Kowa Pharmaceuticals America, Inc. (2016)
All rights reserved.
GEN-1214
August 2016
Trim: 4.75”
Live: 4.25”
Kowa Pharmaceuticals is committed to
developing and delivering safe, effective
solutions in the field of cardiometabolic
therapeutics. We do this by maintaining high
ethical and professional standards—and it
all starts with people. By empowering our
employees to live this mission, we can
create a healthier vision for the future.
Science drives our business, and passion drives our science. At Regeneron, we bring
innovative thinking to the
discovery, development and
commercialization of treatments
that help improve the lives
of patients in need. IMPROVING PATIENT
ACCESS
Upsher-Smith Laboratories, Inc. is committed to providing
healthcare solutions that aim to deliver better outcomes and
enhance life. In pursuit of that mission, we’re dedicated to
partnering with managed care organizations to improve patients’
access to medications they need.
What sets us apart from our competitors is our long track record
of strong relationships and reliable service. We work hard to
offer quality, affordable medications, ranging from generics to
central nervous system (CNS) products, which we strive to keep
in consistent supply. And we can always be counted on to sell our
products at prices that deliver good value.
It is our belief that when time and money are saved, everyone
benefits — especially patients.
Learn more by contacting our managed care team at 1-800-654-2299.
Upsher-Smith Laboratories, Inc., 6701 Evenstad Drive, Maple Grove, MN 55369
© 2016 Upsher-Smith Laboratories, Inc. 110767.02
1-800-654-2299
Established 1999
Please join us in thanking the following sponsors
for their support of this year’s Annual Meeting.
PARTN ER S
P R E SID EN TIAL SPO N SO R S
E X ECU TIVE SPO N SO R S
G EN ER AL SPO N SO R S
Join us next year
sPCMA Business Forum 2017
PCMA Annual Meeting 2017
March 8 & 9
September 25 & 26
Hilton Bonnet Creek
Orlando, FL
The Westin Kierland
Scottsdale, AZ
pcmanet.org